The initial public offering (IPO) of Asston Pharmaceuticals Ltd witnessed strong investor demand, with the issue being oversubscribed by 61.15 times on its final day, July 11, 2025. The IPO, which opened on July 9, 2025, aimed to raise ₹27.56 crores through a fresh issue of 22.41 lakh shares. The IPO price band was fixed at ₹115 to ₹123 per share, with a face value of ₹10.
Subscription Details
The IPO received enthusiastic responses from all investor categories. By midday on the last day, the IPO was subscribed 46.24 times. The retail investors' portion was subscribed 53.62 times, while the qualified institutional buyers (QIBs) and non-institutional investors (NIIs) categories were subscribed 8.41 times and 79.09 times, respectively. Earlier in the day, at the end of the second day, the IPO had been subscribed 13.84 times. The NII portion was subscribed 19.67 times, the retail portion 16.66 times, and the QIB portion 4.47 times.
Grey Market Premium (GMP)
The grey market premium (GMP) for Asston Pharmaceuticals IPO has shown an upward trend. On July 11, 2025, the GMP reached ₹30, compared to a low of ₹10 on July 5. This indicates that the estimated listing price could be ₹153 per share. However, it's important to note that GMP is volatile and should not be the sole basis for investment decisions. Subject to Sauda for the IPO was ₹22,800 as of today.
IPO Details
Asston Pharmaceuticals IPO is a SME IPO with the aim to raise ₹27.56 crores. The issue comprises a fresh issue of 22.41 lakh shares. The IPO price was fixed between ₹115 and ₹123 per share. The minimum lot size for an application is 1,000 shares, requiring a minimum investment of ₹2,30,000 for retail investors. For High Net Worth Individuals (HNIs), the minimum investment is for 3 lots (3,000 shares), amounting to ₹3,69,000.
The IPO opened on July 9, 2025, and closed on July 11, 2025. The allotment is expected to be finalized on July 14, 2025, and the shares are scheduled to be listed on BSE SME on July 16, 2025.
Company Overview
Asston Pharmaceuticals Ltd, established in 2019, is involved in manufacturing and exporting pharmaceutical formulations and nutraceutical products. The company offers a wide range of products, including tablets, capsules, sachets, and syrups, across various therapeutic categories like analgesics, antibiotics, and vitamins. Asston Pharmaceuticals is FDA certified and complies with Quality Management System (QMS) standards.
Financial Performance
The company has shown consistent growth in revenue and profit. In FY25, Asston Pharmaceuticals reported a revenue of ₹25.61 crores, compared to ₹15.84 crores in FY24. The company's profit after tax (PAT) also increased significantly, from ₹1.36 crores in FY24 to ₹4.33 crores in FY25.
Objectives of the Issue
The funds raised through the IPO will be utilized for:
Key Dates
Recommendation
While the IPO has received strong subscription and the company has demonstrated financial growth, investors should consider all factors and risks before making an investment decision.
